Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma Useful Prognostic Tools in the Rituximab Era

被引:53
作者
Ho, Ching-Liang [1 ]
Lu, Chieh-Sheng [1 ,2 ]
Chen, Jia-Hong [1 ]
Chen, Yu-Guang [1 ]
Huang, Tzu-Chuan [1 ]
Wu, Yi-Ying [1 ]
机构
[1] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Hematol & Oncol, Taipei 114, Taiwan
[2] Kaohsiung Armed Forces Gen Hosp, Dept Internal Med, Kaohsiung, Taiwan
关键词
POSITRON-EMISSION-TOMOGRAPHY; R-CHOP; SURVIVAL; CLASSIFICATION; CHEMOTHERAPY; INFLAMMATION; IMPACT; CANCER; IPI;
D O I
10.1097/MD.0000000000000993
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), and absolute lymphocyte count/absolute monocyte count prognostic score (ALC/AMC PS) have been described as the most useful prognostic tools for patients with diffuse large B-cell lymphoma (DLBCL). We retrospectively analyzed 148 Taiwanese patients with newly diagnosed diffuse large B-cell lymphoma under rituximab (R)-CHOP-like regimens from January 2001 to December 2010 at the Tri-Service General Hospital and investigated the utility of these inexpensive tools in our patients. In a univariate analysis, the NLR, LMR, and ALC/AMC PS had significant prognostic value in our DLBCL patients (NLR: 5-year progression-free survival [PFS], P = 0.001; 5-year overall survival [OS], P = 0.007. LMR: PFS, P = 0.003; OS, P = 0.05. ALC/AMC PS: PFS, P < 0.001; OS, P < 0.001). In a separate multivariate analysis, the ALC/AMC PS appeared to interact less with the other clinical factors but retained statistical significance in the survival analysis (PFS, P = 0.023; OS, P = 0.017). The akaike information criterion (AIC) analysis produced scores of 388.773 in the NLR, 387.625 in the LMR, and 372.574 in the ALC/AMC PS. The results suggested that the ALC/AMC PS appears to be more reliable than the NLR and LMR and may provide additional prognostic information when used in conjunction with the International Prognostic Index.
引用
收藏
页数:12
相关论文
共 30 条
  • [1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    Alizadeh, AA
    Eisen, MB
    Davis, RE
    Ma, C
    Lossos, IS
    Rosenwald, A
    Boldrick, JG
    Sabet, H
    Tran, T
    Yu, X
    Powell, JI
    Yang, LM
    Marti, GE
    Moore, T
    Hudson, J
    Lu, LS
    Lewis, DB
    Tibshirani, R
    Sherlock, G
    Chan, WC
    Greiner, TC
    Weisenburger, DD
    Armitage, JO
    Warnke, R
    Levy, R
    Wilson, W
    Grever, MR
    Byrd, JC
    Botstein, D
    Brown, PO
    Staudt, LM
    [J]. NATURE, 2000, 403 (6769) : 503 - 511
  • [2] Inflammation and cancer: back to Virchow?
    Balkwill, F
    Mantovani, A
    [J]. LANCET, 2001, 357 (9255) : 539 - 545
  • [3] Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma
    Cox, M. Christina
    Nofroni, Italo
    La Verde, Giacinto
    Ferrari, Antonella
    Amodeo, Rachele
    Tatarelli, Caterina
    Saltarelli, Francesca
    Veggia, Barbara
    Aloe-Spiriti, M. Antonietta
    Ruco, Luigi
    Monarca, Bruno
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (02) : 265 - 268
  • [4] Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma
    Cox, Maria Christina
    Nofroni, Italo
    Ruco, Luigi
    Amodeo, Rachele
    Ferrari, Antonella
    La Verde, Giacinto
    Cardelli, Patrizia
    Montefusco, Enrico
    Conte, Esmeralda
    Monarca, Bruno
    Aloe-Spiriti, Maria Antonietta
    [J]. LEUKEMIA & LYMPHOMA, 2008, 49 (09) : 1745 - 1751
  • [5] STUDIES OF HUMAN LYMPHOCYTES IN NEWBORN AND AGED
    DIAZJOUANEN, E
    STRICKLAND, RG
    WILLIAMS, RC
    [J]. AMERICAN JOURNAL OF MEDICINE, 1975, 58 (05) : 620 - 628
  • [6] Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas - the PETAL trial
    Duehrsen, Ulrich
    Huettmann, Andreas
    Joeckel, Karl-Heinz
    Mueller, Stefan
    [J]. LEUKEMIA & LYMPHOMA, 2009, 50 (11) : 1757 - 1760
  • [7] Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
    Feugier, P
    Van Hoof, A
    Sebban, C
    Solal-Celigny, P
    Bouabdallah, R
    Fermé, C
    Christian, B
    Lepage, E
    Tilly, H
    Morschhauser, F
    Gaulard, P
    Salles, G
    Bosly, A
    Gisselbrecht, C
    Reyes, F
    Coiffier, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4117 - 4126
  • [8] Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
    Hans, CP
    Weisenburger, DD
    Greiner, TC
    Gascoyne, RD
    Delabie, J
    Ott, G
    Müller-Hermelink, HK
    Campo, E
    Braziel, RM
    Jaffe, ES
    Pan, ZG
    Farinha, P
    Smith, LM
    Falini, B
    Banham, AH
    Rosenwald, A
    Staudt, LM
    Connors, JM
    Armitage, JO
    Chan, WC
    [J]. BLOOD, 2004, 103 (01) : 275 - 282
  • [9] Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone
    Hui, David
    Proctor, Bradley
    Donaldson, Jane
    Shenkier, Tamara
    Hoskins, Paul
    Klasa, Richard
    Savage, Kerry
    Chhanabhai, Mukesh
    Gascoyne, Randy D.
    Connors, Joseph M.
    Sehn, Laurie H.
    [J]. LEUKEMIA & LYMPHOMA, 2010, 51 (09) : 1658 - 1667
  • [10] Li ZM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041658, 10.1371/journal.pone.0053176]